Home > Healthcare > Medical Devices > Diagnostic Devices > Minimal Residual Disease Testing Market
Minimal Residual Disease Testing Market Share
- Report ID: GMI5870
- Published Date: May 2023
- Report Format: PDF
Minimal Residual Disease Testing Market Share
Some of the major minimal residual disease testing market players operating in the minimal residual disease testing industry are
- Adaptive Biotechnologies
- Amgen Inc.
- AstraZeneca
- Bio-Techne
- Bristol-Myers Squibb Company
- Exact Sciences Corporation
Frequently Asked Questions (FAQ) :
Minimal residual disease testing industry size was USD 2.4 billion in 2022 and will record over USD 4.1 billion by 2032 due to the rising need for measuring the effectiveness of treatment and helping doctors confirm & monitor remissions.
The leukemia application segment reached USD 891 million in 2022 driven by the increasing burden of the disease in the region
Minimal residual disease testing market share from hospitals may exceed USD 1.9 billion by 2032 due to the high prevalence of cancer worldwide.
Demand for minimal residual disease testing in the U.S. may reach USD 1.8 billion by 2032 owing to the rising adoption of advanced cancer diagnostic tests in the region.
Minimal Residual Disease Testing Market Scope
×
Get a free sample of
Minimal Residual Disease Testing Market
Inquiry Before Buying
Get special pricing options on this report
Request Sectional Data
Over 70% of our clients customize reports to fit their needs. Please tell us how you would like to customize yours
below